---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001959"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:42:45.653258+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY

## Summary
- Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.
- Full year 2025 preliminary revenue $41.5-42.0M, YoY growth 11-13%.
- CEO cites strong Ameluz sales execution and December pricing adjustment driving record quarter.
- Recent transaction with Biofrontera AG expected to improve gross margin profile and strengthen finances.
- Final Q4 and full year 2025 results to be reported in March 2026.

## SEC filing metadata
- accession: 0001493152-26-001959
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/0001493152-26-001959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001959
- JSON: https://secwatch.observer/filing/0001493152-26-001959.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.